All posts by Rian

Allergic to WiFi (so let’s sue the city)

America: where’s it’s your God-given right to sue anyone or anything for whatever the hell you want, no matter how absurd it is.

God bless the tinfoil hat brigade:

Arthur Firstenberg says he is highly sensitive to certain types of electric fields, including wireless Internet and cell phones.

“I get chest pain and it doesn’t go away right away,” he said.

Firstenberg and dozens of other electro-sensitive people in Santa Fe claim that putting up Wi-Fi in public places is a violation of the Americans with Disabilities Act.

Psst, Arthur, this is what we call a somatization disorder.

Sante Fe, the rest of the country is laughing at you.

Quietly influential

I chuckle every now and again when I see the MSM reporting on blogs. The usual suspects almost always turn up: TechCrunch, the HuffPo, GigaOM, BuzzMachine — as well as a smattering of the hot blogs du jour. This time it was Steve Rubel’s MicroPersuasion and Passive Aggressive Notes.

I must confess some incredulity, because I have never seen Ars Technica mentioned in a story that focuses specifically on blogs. This despite being relegated to merely a “blog” (albeit acknowledged as an influential one) most of the time by the mainstream media when they reference a story that Ars breaks.

Now, the HuffPo is a huge website. Probably a little bigger than Ars with 5.7M unique readers per month. TechCrunch is markedly smaller, and GigaOM is smaller still (1.37M pageviews/month or so).

It makes me wonder why these particular blogs are chosen. Is it because the stories about blogs are by their nature more noise than substance? Indeed these stories are often widely hyped when they hit and will make their way around the ‘sphere several times before disappearing like yesterday’s newspaper. (The blogosphere echochamber at its finest.) Ars seems to be anti-hype most of the time. It’s been known to take a somewhat dim and sometimes even contrarian view to what’s hot in the blogosphere this week — “The Cloud!“, death by blogging! — if indeed what the blogosphere is focusing on this week is even worth talking about at all. (Usually it’s not.)

So here are some sites that Business Week may want to think about including, because these sites are the real movers and shakers in the Internet publishing world. This list is by no means comprehensive, and I make no comments about their content or quality of the sites, only their size. This list isn’t sorted in any meaningful way:

For comparison, TechCrunch sits at ~7.5M pageviews per month, and Ars Technica sits at ~30M.

Gardasil: DTC advertising via your college bookstore

Merck is advertising Gardasil directly to college students that utilize Barnes and Noble’s bkstore.com. For those unfamiliar, bkstore.com has a plugin structure where students log on to their college’s bookstore, choose their class number (e.g. PHRM 328), and their books are loaded up, and you can either pick them up or have them shipped to you. No going to stand in lines or trying to figure out what books you need. One click shopping at it’s most convenient.

So these are college bookstores inadvertently advertising prescription drugs to the entire college population. Well, more accurately, to the population that chooses to have their books shipped to their home, anyway. I don’t know if the bundles that can be picked up have similar advertising info.

Merck’s going about it in a strange way, though. They’re sticking the prescribing information into these boxes. No fancy brochures, just the PI packet, which I find rather bizarre.

I can’t say it doesn’t make sense, or that it’s a terrible idea — I think it’s better than advertising Ambien on television — but it does make me wonder what’s next… Cephalon advertising Provigil to high school and college kids? Med students? Pharmacy students?

Hey, why not?

(No discounts for having advertising in your box of books, either. ;) )

On the Condé Nast Ars Technica acquisition

So the hot news in the blogosphere this week has been the acquisition of Ars Technica by Condé Nast. TechCrunch broke the story on Friday, but there was no official word from Ars until yesterday due to an embargo. Anyway, in that time, there has been quite a lot of discussion on the valuation of “blogs” — or the overvaluation thereof, as the thinking in the blogosphere seems to be.

Silicon Valley Insider:

Ars’ 8-person news operation will be folded into Wired Digital, which is run by CondéNet.

This is almost, but not quite, correct. Ars will remain its own brand, and will retain its own staffing. Ars will not be “folded” into Wired, though they will continue to exist under the Wired Digital umbrella (which is turn is owned by CN). In a very real sense, they will be friendly competitors. This is not unlike two newspapers owned by a larger parent company competing with one another in overlapping geographic territories. (A common practice in traditional print media.)

I guess I’m a little bit stuck on calling Ars a “blog”, however. Ars is a news site with real, investigative reporting and thoughtful analysis, longer, multi-page in-depth investigative and explanatory pieces and guides, and has been around since before people had even heard the word “blog”. If anything Ars is a news site and a focused blog network all rolled into a single brand. (As opposed to the old Weblogs, Inc. model where each blog was separate and had its own flavor.) The journals section of the site combines six different journals under one umbrella — each of which has a large enough audience on their own to be considered very successful. Particularly Infinite Loop and Opposable Thumbs.

On the $25 million

There was a collective gasp in the blogosphere over the price commanded by Ars. Frankly, I’m not really sure why. When I first heard the number, I thought it was low, given the amount of traffic that Ars gets, which is different than the traffic that sources that measure such things think.

The usual suspects like Comscore and Alexa are referenced as though they’re absolutes. The truth is that Alexa is horribly inaccurate, as anyone who runs a website with a tech-savvy audience will tell you. (Who do you know that uses the Alexa toolbar?) Nonetheless, these same sites will turn around and quote the stats as though they’re somehow magically more meaningful for another web property. It doesn’t really make a lot of sense if you stop and think about it.

Maroon Ventures:

Some key stats:

  • Purchase Price $25,000,000
  • Monthly Unique Visitors: 1,500,000
  • Monthly Pageviews: 4,000,000

Okay, let’s have some fun. Let’s assume that this acquisition helps set the market price for the internet blog pure play. What it this acquisition telling us?

  • Value of the Monthly Unique User: $16.65/unique
  • Value of the Monthly Pageview: $6.25/pageview

Unfortunately, these numbers aren’t correct, no matter what TechCrunch would have you believe, but to be fair to Chris, Ken hadn’t posted the official word until yesterday. As far as TechCrunch is concerned, more diligent reporting would have led to Federated Media’s information page on Ars for potential advertisers — so they should know better.

Here’s the official word on the acquisition, straight from the horse’s mouth:

We have an amazing community, both in terms of its size (5+ million readers, as tracked privately by Quantcast) and in terms of its contributions (12 million posts, thousands upon thousands of news tips, recommendations, and corrections). Our community is unparalleled, in my not so humble opinion, and it’s a big reason why this year we’re serving more than 30 million page views each month. (I’ve seen lots of folks citing Comscore numbers… they’re horribly, horribly wrong).

Now you might think that the $25 million isn’t so unreasonable. Taking a look at the old Federated Media advertising numbers[1], you can see that Ars commands about $38 per thousand pageviews.

30,000,000 / 1,000 * $38 * 3 ads on each page = $3,420,000

That’s $3.42M per month in advertising revenue that Ars is generating. Yes, FM takes a cut of that, but Ars has other, smaller revenue sources, such as affiliate referal dollars and Ars-branded merchandise for sale, so we’ll call the difference a wash.

Now that’s revenue, not profit. There’re 8 full-time employees, as well as webhosting for the main site, the cost of the CDN (they’ve been using CacheFly to serve all static content), the cost of the discussion forums (currently a hosted solution: groupee’s eve product) as well as several ICs that do web development, CMS development and other technical work for them.

A typical business acquisition is 3-5x annual profit[2], so that means the four main founders (Ken, Jon, Ben Rota, and Panders) were taking in an annual profit of ~$6.25M per year split however they were splitting it.

Final thoughts

I often wonder why such blatantly incorrect numbers are often bandied about when the truth is usually freely available if you look for it. It’s no secret just how many pageviews Ars has been doing: they’re posted on Federated Media’s website for anyone who wants to advertise there. And you can bet your shiny metal ass that they’re accurate — and more likely (*gasp*) conservative. When millions of dollars are changing hands on a monthly basis, there are very accurate accounting measures going to be built in so buyers can have faith that they’re getting what they pay for.

And for those wondering whether Ars is or is not going to jump the shark, I have two thoughts for you:

First, this isn’t the first time Ars Technica has been part of an online network. Early readers of Ars may recall that Ars was once part of the now-defunct Maximum PC network. Then, as now, the larger and more focused you are, the more you command in CPM rates.

Second, having known Jon and Ken since 2000, I can say with a great deal of personal conviction that Ars isn’t going anywhere, and that thing most certainly will change, but they will change because that’s what the guys steering the ship (Ken, Jon, and possibly Eric) want — not because it’s what Condé Nast wants. So if you see something change in the future, you can feel free to continue pointing the finger at the founders, not at Condé Nast. ;)

Footnotes:
[1]I’ve linked to a screenshot because the original FM link will inevitably disappear in the near future as Ars Technica will no longer be outsourcing their advertising to Federated Media.

[2]This will obviously change depending on your industry.

On panic disorder and benzodiazepine use

I’m taking a class just for fun right now — psychopharmacology — and the discussions that crop up are quite excellent. Many of the students are prescribers in my area, and I fill their scripts on a regular basis. It makes for an interesting, voyeuristic look into their thought processes given some of the case studies. That is, I know who they are, but they don’t know who I am…

This week’s topic is panic disorder and relapse in patients with and without a history of substance abuse. Fun topic, really, and one close to my heart.

Case study:

[You are] working with a 32 year old man who comes to you for an evaluation of panic in August in Lowell. He meets the diagnostic criteria for panic disorder and has been experiencing untriggered episodes for the last 2 months. Name three factors that would guide your selection of medication and then discuss your pharmacologic plan for this unfortunate man.

One of the responses — by a prescriber in my area — was to encourage deep breathing, progressive relaxation, identifying triggers and avoiding the situation, CBT, and starting an SSRI. If panic continues, start a benzo.

This strikes me as fairly typical approach for a primary care provider in dealing with someone who presents during an acute panic attack, but I think that it’s doing the patient a disservice. Perhaps it’s also a typical response for a psychiatrist who is afraid to use benzodiazepines.

I’ll post my response here, verbatim, because I think there’s a deep (and common) misunderstanding of what panic is, and what having a panic attack is like.

It seems like you’re thinking of panic as something that can be gotten out of, as though it’s a normal fight-or-flight type response where removal from a stressful stimulus means no more panic.

This is dangerous thinking, and forgive me if I’ve read you wrong.

It can be harder than perhaps some practitioners think to identify a trigger. While triggers can often be identified, I think it’s important to note that when a patient first presents, and you make a diagnosis of panic disorder, discovering these triggers will be more complex than simply avoiding a stressful situation, or simplifying and eliminating stressors from one’s life. (Which is a very time-consuming process.)

You can’t turn the ship on a dime.

Please don’t fall victim to the idea that because you’ve been scared out of your wits a few times and your heartrate went up and your BP went through the roof that that is a panic attack. It’s not. Panic attacks usually appear in a completely idiopathic manner, particularly the first time they hit. It’s not an “Oh Gee, you scared me,” type of thing, it’s more of a “DEAR GOD I’M DYING, SOMEONE PLEASE DIAL 911” type of thing.* (The caps are appropriate there. ;) )

Panic attacks can, and do hit without any warning in an otherwise comfortable, relaxed setting. Watching a movie in your living room, for example.

It’s not like [situation] -> panic attack a few minutes or an hour later with a clear antagonist. It can come days after the stressors. It can also take a few weeks and lots of practice to build up an arsenal of effective coping mechanisms to return oneself to a calming state in the middle of an active attack.

Re: Deep breathing. This can also be problematic as at the point where one’s lungs are fully inflated one can experience a PVC or PAC, which is VERY disconcerting to someone who’s already acutely aware of what their heart is doing. I can actually trigger PVCs in myself by doing this.

I don’t mean to lecture. I’m not the professor, and perhaps I’ve read too much between the lines of what you’ve written. As someone who didn’t get out of bed for 3 weeks the first time I had a panic attack, I feel very strongly about the issue, and combatting it aggressively rather than taking a more laid back, it’ll-fix-itself approach. Particularly this: “deep breathing, progressive relaxation, identifying triggers and avoiding the situation, CBT, [etc.]”

Those are all great long-term approaches, but the short-term is what someone with panic disorder in an active phase cares about most. Long term stuff can come after, just get me through right now.

And I am keenly aware that my personal experience should never cloud my clinical judgement inasmuch as that is humanly possible.

* I tried to dial 911 my first time, in the middle of a biochemistry lecture, no less. But I couldn’t see well enough to dial the number. In retrospect, knowing what I know now, I’m glad I couldn’t because that would have been a misuse of medical resources. :p

Early in panic, people are usually not capable of accessing the skills to use behavioral coping mechanisms. You usually need to halt the panic quickly and this is where BZDs are needed. Panic is such an uncomfortable and painful experience, the BZD’s are in a way like pain medications in the early stages of treatment.

The more you talk, the less I believe you

Something I’ve noticed for years: the more a patient talks at you, the more likely they are to be lying. They talk and talk and talk, and nothing of substance comes out. It’s a smokescreen for something else they want. They tell you their life story, and then ask for an early fill on their Vicodin as though the two are somehow related.

Do they think I’m stupid? I can’t count the number of times I’ve put the phone down with the person still talking at me (without having said more than “May I help you?”) done something, and then come back with them still blowing hot air.

The more words someone uses, the greater the chances are that they’re full of shit.

This is in contrast to someone with a legitimate issue who will tell you their story in as few words as possible, and then ask what they need to do. Even people who typically blow smoke talk less when they’re actually telling the truth and they have, for instance, a police report to back it up.

Every retail pharmacist in the world knows exactly what I’m talking about, and I’m sure most ED types do too. Remarkable that the bottom-feeders on the planet haven’t figured out that if they just kept their mouths shut, I’d be 2-3x more likely to believe them. I would have thought such a skill would be accidentally uncovered and remembered. But perhaps idle chatter is the verbal form of a nervous twitch, and many of these folks are halfway decent candidates for the Darwin Awards anyway, so I shouldn’t be surprised that they haven’t learned from past successes.

In any event, they’d all be shitty poker players.

Drug advice from Consumers’ Reports

Genetic drugs

This is going to be quick and dirty because I’ve got some other things to do, but I’ve been putting it off far longer than I’ve meant to. (No time like the present, right?) In the January 2008 issue, CR ran a feature on how people could save money on prescriptions meds. Generally speaking, I am in favor of this kind of thing. I like people to know the alternatives, and how they can save money.

Generally-speaking, it’s not a good idea to have word-choice errors in a piece that’s supposed to be professional. (See image.) Maybe they should get a medically-trained copy editor and add them to the list of peer-reviewers. Ridiculous.

I’ve re-created the table they have:

 

Consumers Reports drug table

I’ll go through it quickly:

Zyrtec is now available OTC, and is comparable to the cost of Claritin. Claritin doesn’t work for a goodly number of folks, so Zyrtec is a better option. Zyrtec went OTC the month after this was published — and it wasn’t a big secret that it was going to happen.

For ADHD, Strattera is not a popular option. It doesn’t work for many people, and ADHD people have a hard time remembering to take their meds consistently, which makes this option less desirable, particularly where it takes a little while for Strattera to begin working. I’m surprised this drug was listed at all, as it’s rarely a first-line choice for ADHD spectrum disorders. Even comparing atomoxetine (an NRI) to methylphenidate (a stimulant) is a bit… off, and IMO, does the consumer no favors. Strattera is usually used where someone is at risk for drug abuse or has comorbidities like hypertension or anxiety (iatrogenic or otherwise) and so cannot tolerate stimulants.

Depression… don’t have much to say there. Fluoxetine tends to be more stimulating than Lexapro, and there are other subtle differences (half-life, solubility, etc.), but for most people, switching from one to the other is probably not impossible.

As for Diabetes… well. Using a biguanide is usually the first step in treating metabolic syndrome, and then you add other meds on top of that. I’d be skeptical of any doctor who used Actos before using metformin without a given reason. Diabetes treatment tends to go in stepwise fashion like most other chronic illnesses. Removing a TZD from a pre-existing diabetic regimen can be done, but it’s not as simple (or desirable) as this little blurb makes it seem. And a TZD isn’t normally used as monotherapy. Frankly, I think suggesting Glucotrol rather than metformin would have made more therapeutic sense. And in terms of good use of space, I think think they would have been better going after the ARBs and hypertension in general here.

Heartburn and GERD? Nexium 20mg? Who even uses the 20mg strength Nexium? I see it maybe 3 times a year. They should have done 40mg Nexium and suggested 40mg of Prilosec. (Hilarious sidenote: 40mg Prilosec caps (the one without a generic) cost ~$60 more than 40mg Nexium caps.) Generally, though, this one wasn’t too bad.

Insomnia: Eh, probably okay I guess. Insomnia is a poorly-treated condition in this country, and frankly, I’d rather see other methods explored before reaching for the BZRAs at all. But the BZRAs are the easiest, and they keep patients happy. Unfortunately, not enough time is spent diagnosing the underlying causes of insomnia, resulting in a poorly quality of life. There are differences in the polysomnograms of patients on eszopiclone and zolpidem, too, which are not talked about. I’d rather see ramelteon tried before any BZRA, and also see a psychologist about diagnosing an underlying cause for the insomnia in the first place, if a primary care provider cannot take the time (due to financial considerations) to do it themselves. And 5mg of Ambien might help with sleep induction, but the relatively short half-life will do next to nothing for those with sleep maintenance problems.

I’d rather have seen trazodone suggested, since insomnia is usually secondary to some kind of other psychiatric disturbance — a type of uni- or bipolar depression.

Not much to say about arthritis, but I hardly ever see Celebrex used anymore. Now that it stands alone as a COX-2 inhibitor, it’s also the most expensive anti-inflammatory in the book and insurers are loathe to use it. I’d rather see diclofenac recommended over ibuprofen, and suggesting that 400mg of ibuprofen daily is anywhere near equivalent to 200mg of celecoxib is laughable.

Schizophrenia. SCHIZO-FREAKIN-PHRENIA? CR is going to tackle SCHIZOPHRENIA in an article about how to save money?!?! I am having difficulty wrapping my brain around that one.

But okay, here goes. Schizophreniform disorders should be managed by a psychiatrist or psychiatric NP, IMNSHO. Diagnosis is tricky, and management is always tricky. All that said… while first generation antipsychotics are often as effective as their second gen counterparts, I am extremely leery of merely saying that Y could be substituted for X. At least CR has the good grace to state “The antipsychotics have major side effects and response to them is highly variable” — AKA “Take our advice with a monster grain of salt.” Not the least of the worries are akathisia, tardive dyskinesia, other extrapyramidal symptoms, weight gain, and about a bazillion other possible side effects. My mind is still boggled that they even went there.

Curiously, however, discontinuation rates of perphenazine in schizophrenic patients are lower than with any second gen antipsychotic save olanzapine (Zyprexa) — though people tended to d/c Zyprexa due to its metabolic effects and weight gain, and perphenazine for its extrapyramidal symptoms. Something to consider, I suppose.

All things considered, it’s nice to see the mainstream media promoting saving money on drugs, but it bugs me that they did it in the way that they did.

Oops

Absolutely perfect timing with Dr Dino’s Oops Meter.

Got a phonecall from an FP’s office across the street from the pharmacy. Medicaid patient had brought in his Risperdal Consta injection for his bi-weekly shot. The nurse dropped the injection in the office, which broke it, resulting in some non-emergent, but non-trivial lacerations to herself in the process.

Could we get another one? Of course, it’s 4pm on a Friday, and MassHealth doesn’t do lost/damaged precription overrides — if they did, their budget would probably double (TAP doesn’t make this shit up, you know) — but could we pleeeeeeease try. And they would, of course, call MassHealth themselves.

Risperdal Consta is about $650 per dose.

Of course the answer was no, but with both of us on the phone, MassHealth said they could do it tomorrow (that would be today, I guess) as a once-in-a-lifetime early-fill don’t-ever-ask-again override.

I’m so glad it worked out, and I feel terrible for this nurse. She’s probably wishing she had dropped some cyanocobalamin instead. We’d have just given it to them for nothing had it been something like that.

Based on Dino’s examples on the oops meter, I’d give this a solid 8. Right next to breaking wind in front of your boss. On the elevator.